Medicamen Biotech Past Earnings Performance
Past criteria checks 2/6
Medicamen Biotech has been growing earnings at an average annual rate of 4.1%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 4.5% per year. Medicamen Biotech's return on equity is 5.6%, and it has net margins of 7.4%.
Key information
4.1%
Earnings growth rate
1.9%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 4.5% |
Return on equity | 5.6% |
Net Margin | 7.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%
Mar 17Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00
Sep 13Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 19There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price
Dec 03Revenue & Expenses BreakdownBeta
How Medicamen Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,707 | 127 | 286 | 0 |
30 Sep 23 | 1,597 | 133 | 262 | 0 |
30 Jun 23 | 1,497 | 154 | 227 | 0 |
31 Mar 23 | 1,409 | 148 | 218 | 0 |
31 Dec 22 | 1,250 | 137 | 198 | 0 |
30 Sep 22 | 1,220 | 137 | 178 | 0 |
30 Jun 22 | 1,210 | 143 | 159 | 0 |
31 Mar 22 | 1,154 | 149 | 156 | 0 |
31 Dec 21 | 1,139 | 158 | 136 | 0 |
30 Sep 21 | 1,142 | 150 | 123 | 0 |
30 Jun 21 | 1,125 | 140 | 97 | 0 |
31 Mar 21 | 1,127 | 121 | 96 | 0 |
31 Dec 20 | 1,150 | 110 | 97 | 0 |
30 Sep 20 | 1,174 | 116 | 100 | 0 |
30 Jun 20 | 1,222 | 123 | 97 | 0 |
31 Mar 20 | 1,255 | 133 | 101 | 0 |
31 Dec 19 | 1,353 | 136 | 90 | 0 |
30 Sep 19 | 1,241 | 124 | 85 | 0 |
30 Jun 19 | 1,210 | 123 | 79 | 0 |
31 Mar 19 | 1,227 | 120 | 86 | 0 |
31 Dec 18 | 1,187 | 110 | 94 | 0 |
30 Sep 18 | 1,229 | 117 | 97 | 0 |
30 Jun 18 | 1,183 | 108 | 91 | 0 |
31 Mar 18 | 1,115 | 101 | 99 | 0 |
31 Dec 17 | 1,045 | 94 | 100 | 0 |
30 Sep 17 | 962 | 81 | 95 | 0 |
30 Jun 17 | 912 | 65 | 75 | 0 |
31 Mar 17 | 825 | 52 | 71 | 0 |
31 Dec 16 | 782 | 58 | 55 | 0 |
30 Sep 16 | 723 | 26 | 52 | 0 |
30 Jun 16 | 673 | 18 | 54 | 0 |
31 Mar 16 | 673 | 5 | 61 | 0 |
31 Dec 15 | 679 | -13 | 137 | 0 |
30 Sep 15 | 667 | -2 | 137 | 0 |
30 Jun 15 | 760 | -1 | 65 | 0 |
31 Mar 15 | 779 | 4 | 68 | 0 |
31 Dec 14 | 816 | 0 | 129 | 0 |
30 Sep 14 | 807 | -1 | 126 | 0 |
30 Jun 14 | 738 | -1 | 57 | 0 |
31 Mar 14 | 732 | 1 | 123 | 0 |
31 Dec 13 | 696 | -7 | 125 | 0 |
30 Sep 13 | 697 | -20 | 128 | 0 |
30 Jun 13 | 717 | -37 | 135 | 0 |
Quality Earnings: MEDICAMEQ has high quality earnings.
Growing Profit Margin: MEDICAMEQ's current net profit margins (7.4%) are lower than last year (11%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MEDICAMEQ's earnings have grown by 4.1% per year over the past 5 years.
Accelerating Growth: MEDICAMEQ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MEDICAMEQ had negative earnings growth (-7.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: MEDICAMEQ's Return on Equity (5.6%) is considered low.